Aaron Lorenzo

The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today)

Pharmacyclics Steps Back Up With Pivotal Study Of Xcytrin

Dec. 20, 2002

By Aaron Lorenzo

Pharmacyclics Steps Back Up With Pivotal Study Of Xcytrin

Dec. 20, 2002

By Aaron Lorenzo

Neurocrine Signs Blockbuster Deal With Pfizer In Insomnia

Dec. 20, 2002

By Aaron Lorenzo

The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today)

Angiogenix Raises $12M In Series C For Acclaim Product

Dec. 19, 2002

By Aaron Lorenzo

Articles by Aaron Lorenzo

Transave Raises $12M For Work Targeting Diseases Of The Lung

Valentis Licenses Technologies For Use In Schering Gene Efforts

Endo Comes Up Short With One Product, Files NDA For Another

Endo Comes Up Short With One Product, Files NDA For Another

Valentis Licenses Technologies For Use In Schering Gene Efforts

Neurocrine Signs Blockbuster Deal With Pfizer In Insomnia

Pharmacyclics Steps Back Up With Pivotal Study Of Xcytrin

Pharmacyclics Steps Back Up With Pivotal Study Of Xcytrin

Neurocrine Signs Blockbuster Deal With Pfizer In Insomnia

Angiogenix Raises $12M In Series C For Acclaim Product

Today's news in brief

Cas and effect: Merck’s phase III ripples HIF-2α space

Brain’s hidden tau-clearing pathway uncovered

News in brief

MSD synthesizes α-synuclein PET agents